Low Dose Aspirin Alerts in High-Risk Pregnancies

Launched by GEISINGER CLINIC · Apr 6, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how an electronic tool, called a best practice alert, can help healthcare providers recommend low-dose aspirin to pregnant women who are at high risk of developing a condition called preeclampsia. Preeclampsia can lead to serious complications for both the mother and baby, and taking low-dose aspirin may help reduce this risk. The researchers believe that by using this electronic tool, more healthcare providers will suggest low-dose aspirin to their patients than they currently do.

To participate in this study, women need to be receiving prenatal care at Geisinger and have their first prenatal visit before they are 28 weeks pregnant. They must also be identified as high risk for preeclampsia based on specific guidelines, meaning they have at least one risk factor for the condition. Unfortunately, women who are not pregnant, have not had an early prenatal visit, or have certain medical reasons that prevent them from taking aspirin will not be eligible. Participants can expect to help improve care for future patients while potentially receiving personalized recommendations about low-dose aspirin during their pregnancy.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Receiving prenatal care within Geisinger
• • Initial prenatal visit prior to 28 weeks gestation
• • Determined to be high risk for preeclampsia based on the modified United States Preventive Services Task Force and American College of Obstetrics and Gynecology criteria (at least 1 high risk factor)
• Exclusion Criteria:
• • Not pregnant
• • No prenatal visit prior to 28 weeks gestation
• • Maternal-Fetal Medicine only visits
• • Not meeting the modified USPSTF high-risk criteria
• • Contraindication to aspirin, including allergy